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OBJECTIVES The aim of this study was to compare the effectiveness of the implantable cardioverter
defibrillator (ICD) and medical strategies for prevention of arrhythmic events and death.
BACKGROUND The ICD is a potential strategy to reduce mortality in patients at risk of sudden death.
METHODS The MEDLINE, EMBASE, and Cochrane Library electronic databases were searched
from January 1966 to April 2002. All published randomized controlled trials comparing
ICD implantation with medical therapy were reviewed. Four independent reviewers
extracted data on all-cause mortality, nonarrhythmic death, and arrhythmic death using
a standardized protocol.
RESULTS Nine studies including over 5,000 patients were synthesized using both fixed-effects and
random-effects models. The primary and secondary prevention trials showed a significant
benefit of the ICD with respect to arrhythmic death, with relative risks (RR) of 0.34 and 0.50,
respectively (both p  0.001). The mortality benefit of the ICD was entirely attributable to
a reduction in arrhythmic death (all trials: p  0.00001). Whereas the secondary prevention
trials exhibited a robust decrease in all-cause ICD mortality (RR 0.75; p 0.001), the pooled
primary prevention trials demonstrated decreased all-cause ICD mortality (RR 0.66; p 
0.05) which was dependent on selected individual trials. The disparity in ICD-related
mortality reductions in the primary prevention trials was related to variability in the incidence
of arrhythmic death between individual studies.
CONCLUSIONS Although the ICD decreases the risk of arrhythmic death, its impact on all-cause mortality
is related to the underlying risk of arrhythmia-related death relative to competing causes.
Given the cost of the device strategy, policies of targeted intervention based on the future risk
of arrhythmia are warranted. (J Am Coll Cardiol 2003;41:1573–82) © 2003 by the
American College of Cardiology Foundation
Strategies to improve survival from fatal cardiac arrhythmias
and all-cause mortality in patients at risk of sudden arrhyth-
mic death have included the use of antiarrhythmic drugs
(AAD), the implantable cardioverter defibrillator (ICD), or
both (1–4). An AAD strategy using amiodarone has been
shown to have modest effects on overall survival when
compared with placebo in patients with left ventricular (LV)
dysfunction (5,6). Although meta-analyses of total mortality
and sudden death prevention with amiodarone have dem-
onstrated a 10% to 19% reduction of total mortality (7,8),
the longer term potential for serious adverse effects may
limit the practical usefulness of this therapy in patients at
risk of arrhythmia (9,10).
The ICD strategy is appealing because of its ability to
terminate ventricular arrhythmias reliably, to provide
early defibrillation, and perhaps to decrease or eliminate
the need for concomitant antiarrhythmic medications and
their associated adverse effects. Observational studies
have shown that the ICD provides a survival advantage
over AAD in patients with symptomatic arrhythmias,
particularly in patients with depressed LV function (11–
13). However, the ICD is associated with substantial
costs and, therefore, precise estimates of device effective-
ness are required. The objective of this study was to
compare the effectiveness of medical therapy with the
ICD in patients who are at risk of future episodes of
sudden arrhythmic death and to clarify the issue of
competing risks by analysis of the mode of death.
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METHODS
Search strategy. High-quality randomized trials of primary
or secondary prevention that compared the ICD with
medical therapy (with or without AAD) were identified.
The strategy used to identify studies was developed in
collaboration with the Cochrane Heart Group (14). The
MEDLINE database was searched from January 1966 to
April 2002. A previously published randomized controlled
trial (RCT) filter for use with the MEDLINE electronic
database was employed to optimize the search strategy (15).
Keywords included: defibrillators, implantable; cardioverter;
anti-arrhythmia agents. Amiodarone, sotalol, and names of
other antiarrhythmic agents were searched as textwords.
The EMBASE database was searched from January 1980 to
April 2002. A previously published RCT filter for use with
the EMBASE electronic database was used to optimize the
search strategy (16). The COCHRANE Library and Con-
trolled Trials Register (2002) was also searched. No restric-
tions on language, dose, or ICD type were applied. All
reference lists of pertinent studies were searched by two
reviewers (D.S.L. and L.D.G.). Published study protocols
were evaluated to further clarify specific methodologic
elements for quality assessment. Updated publications per-
taining to any relevant outcomes that were not published in
the primary article were also reviewed.
Study selection. Criteria used to select studies for inclusion
in this review were as follows. 1) Design: RCT comparing
ICD with medical strategy. 2) Population: patients (18
years) who have had an episode of resuscitated sudden death
or symptomatic ventricular tachyarrhythmia or patients who
have a low left ventricular ejection fraction (LVEF) (0.40)
and are thought to be at risk for development of lethal
cardiac arrhythmia. 3) Intervention: ICD versus medical
therapy for the prevention of sudden arrhythmic death.
Studies whose primary objectives were the evaluation of
defibrillation thresholds or mechanism of drug or device
action and/or where the primary end point of interest was
not mortality were excluded. 4) Outcome: at least one of the
reported outcomes was all-cause mortality, cardiac death,
arrhythmic mortality, or cardiac arrest. A QUOROM
statement flow diagram (17) for included and excluded
studies is shown in Figure 1.
Quality assessment and data abstraction. Quality assess-
ment of potentially qualifying studies was performed inde-
pendently by four reviewers (D.S.L., L.D.G., F.C.G., and
P.P.L.). Criteria for quality assessment included: 1) blind-
ing of randomization, 2) complete follow-up, and 3) blind-
ing/objectivity of outcome measurement. Blinding of inter-
vention was not used for quality assessment because the
intervention was surgical. Outcomes of all-cause mortality,
arrhythmic death, and nonarrhythmic death (when avail-
able) were abstracted independently from each included
study. Any potential disagreement was to be arbitrated by
two of the authors (J.V.T. and D.A.A.).
Statistical analysis. Analysis was performed using the
Mantel-Haenszel method. Relative risk (RR) and risk
difference (RD) with 95% confidence intervals (CI) using
the fixed effects model were calculated for the primary/
secondary prevention trials separately and for all the trials in
the overall analysis. If a statistically significant reduction in
the RD was found, the number needed to treat was
calculated (18). Statistical heterogeneity between studies
was identified using the chi-square statistic, and a p  0.10
was deemed statistically significant. If significant statistical
heterogeneity was identified, a random effects analysis was
performed. We performed an overall analysis including all
randomized trials. However, we anticipated clinical hetero-
geneity which was addressed by the performance of separate
analyses of primary and secondary prevention studies and
selected sensitivity analyses. Adverse events are reported
overall as weighted percentages. Fatal perioperative adverse
events included deaths occurring up to 30 days after device
implantation.
RESULTS
Search results. A total of 1,077 potentially relevant articles
were screened, and 1,003 were excluded after examination
of the title and abstract. Of the 74 articles retrieved for
further examination, 51 were excluded for the following
reasons: nonrandomized (41 articles), absence of ICD arm
(2 articles), quality of life outcome (1 article), no useful
outcomes (6 articles), and protocol of ongoing study (1
article). Of the remaining 23 articles, a number were
publications that evaluated the mode of death in the same
patient sample as the primary study publication. There were
16 discrete randomized trials that were subsequently as-
sessed for quality.
Details of the included study designs and trial interven-
tions are shown in Table 1 (19–27). In total, the meta-
Abbreviations and Acronyms
AAD  antiarrhythmic drugs
AVID  Antiarrhythmics Versus Implantable
Defibrillators study
CABG Patch  Coronary Artery Bypass Graft Patch
trial
CASH  Cardiac Arrest Study Hamburg
CAT  Cardiomyopathy Trial
CI  confidence interval
CIDS  Canadian Implantable Defibrillator
Study
ICD  implantable cardioverter defibrillator
LV  left ventricular
LVEF  left ventricular ejection fraction
MADIT  Multicenter Automatic Defibrillator
Implantation Trial
MUSTT  Multicenter Unsustained Tachycardia
Trial
RCT  randomized controlled trial
RD  risk difference
RR  relative risk
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analysis represented a composite of over 5,000 patients.
These studies were multicenter randomized trials spanning
several countries (U.S., Canada, Netherlands, Australia, and
Germany). Five trials were primary prevention studies. The
primary prevention trials identified patients with poor LV
function (LVEF 0.40) who were deemed to be at in-
creased risk of sudden death (Fig. 2). Four randomized trials
were secondary prevention studies that evaluated patients
resuscitated from sudden cardiac death or with symptomatic
ventricular tachyarrhythmias and reduced ejection fraction
(Fig. 2).
Outcomes. Follow-up was nearly complete in these studies
with fewer than 1.5% lost to follow-up in all studies. The
average duration of follow-up was 18 to 20 months in the
Antiarrhythmics Versus Implantable Defibrillators (AVID)
study and the Multicenter Automatic Defibrillator Implan-
tation Trial (MADIT II) and ranged from 27 to 39 months
in MADIT I, the Coronary Artery Bypass Graft Patch Trial
(CABG Patch), the Canadian Implantable Defibrillator
Study (CIDS), and the Multicenter Unsustained Tachycar-
dia Trial (MUSTT). The Cardiac Arrest Study Hamburg
(CASH) and the Cardiomyopathy Trial (CAT) had the
longest follow-up durations: 57 to 66 months. In aggregate,
there were a total of 1,292 deaths in 5,153 patients—
primary prevention (n  3,130) and secondary prevention
(n  2,023).
Primary prevention trials. The MADIT I and MUSTT
studies showed significant reductions in arrhythmic death of
75% and 73%, respectively. In CABG Patch, there was a
trend to decreased risk of arrhythmic death with the ICD;
however, the CI crossed unity (RR 0.55; 95% CI 0.30 to
1.01). When the results were pooled, there was no statistical
heterogeneity (p 0.21), and a significant pooled reduction
in arrhythmic death favoring the ICD (RR 0.34; 95% CI
0.23 to 0.50) was found (p 0.00001). There was no excess
of nonarrhythmic deaths in the ICD group with a pooled
RR of 0.95 (95% CI 0.74 to 1.21) for this end point. For the
end point of all-cause mortality, MUSTT, MADIT I, and
MADIT II found significant reductions in all-cause death
with relative reductions in risk ranging from 29% to 59%
(absolute risk reduction 26%, 23%, and 6%, respectively).
The pooled data (Fig. 3) showed significant benefits in favor
of the ICD with a RR reduction of death from any cause of
34% (p  0.03). The random effects 95% CI of the RR
reduction was 4% to 54%.
Secondary prevention. Individually, both AVID and
CASH demonstrated statistically significant reductions in
arrhythmic death with the ICD, with reported RR of 0.44
Figure 1. QUOROM flow diagram of search results and the process of identification of randomized controlled trials (RCTs) meeting inclusion criteria.
ICD  implantable cardioverter defibrillator.
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Table 1. Summary of Included Primary and Secondary Prevention Studies of Defibrillator Versus Medical Therapy
Randomized
Trials Design/Sites Participants Interventions Outcomes ICD Industry Support
AVID (19) Multicenter RCT with amiodarone
or sotalol as medical therapy
(U.S., Canada)
1,016 patients resuscitated from
near-fatal VT/VF, sustained
VT with syncope, or
sustained VT with
LVEF  0.40 and symptoms
507 randomized to ICD (472 transvenous,
25 thoracotomy, 10 not implanted).
509 randomized to AAD,
475 discharged on amiodarone
Early termination.
Mode of death assessment by
blinded independent events
committee using internal
criteria
None specified
CABG Patch (20) Multicenter RCT with no
antiarrhythmic drugs as
conventional therapy
(U.S., Germany)
1,055 patients undergoing
CABG with LVEF  0.35
and abnormal signal-averaged
ECG with no previous
sustained VT/VF
446 randomized to ICD (434 implants
occurred). 454 randomized to usual
care; no protocol-driven AAD therapy
instituted
Mode of death quality review
and external events
committee using the
modified Hinkle and
Thaler method
Guidant (unspecified type)
CASH (21) Multicenter RCT with amiodarone
or metoprolol as conventional
therapy (Germany)
288 patients resuscitated from
cardiac arrest due to sustained
ventricular arrhythmia
99 randomized to ICD (44 transvenous,
55 thoracotomy). 92 randomized to
amiodarone and 97 to metoprolol.
Initial propafenone arm discontinued
due to excess mortality
Internal criteria for sudden
arrhythmic death
Guidant (Ventak AID/
AICD/P/PRx/Mini)
CAT (22) Multicenter RCT with standard
medical therapy (no protocol-
driven antiarrhythmics) as
conventional therapy (Germany)
104 patients with dilated
cardiomyopathy and
LVEF  0.30
50 randomized to ICD (transvenous).
54 randomized to control
Internal criteria for sudden
death
Guidant (Endotak, Ventak
P2/P3/PrX II/CPI)
CIDS (23) Multicenter RCT with amiodarone
as conventional therapy
(Canada, Australia, U.S.)
659 patients with documented
VF, out-of-hospital cardiac
arrest requiring defibrillation,
VT with syncope, VT with
rate 150/min causing
presyncope or angina in
patient with LVEF  0.35,
or syncope with VT inducible
at EPS
328 randomized to ICD (277 transvenous,
33 thoracotomy, 18 did not receive
ICD). 331 randomized to amiodarone
Death classification by the
method of Hinkle and
Thaler, adjudicated by a
blinded external events
validation committee
None specified
MADIT I (24) Multicenter RCT with
antiarrhythmic drugs as
conventional therapy
(U.S., Europe)
196 patients with MI  3
weeks before entry and
asymptomatic unsustained VT
unrelated to an acute MI and
LVEF  0.35, with inducible
VT not suppressed after
intravenous procainamide
95 randomized to ICD (50 transvenous,
45 transthoracic, 5 did not undergo
device implantation). 101 randomized
to AAD (primarily amiodarone)
Early termination.
Death classification by end
point committee using
Hinkle and Thaler method
Guidant (unspecified type)
MADIT II (25) Multicenter RCT with standard
medical therapy (no protocol-
driven antiarrhythmics) as
conventional therapy
(U.S., Europe)
1,232 patients with MI  4
weeks before entry and
LVEF  0.30
742 randomized to ICD (721 transvenous,
21 did not undergo device
implantation). 490 randomized to
conventional therapy
Early termination.
Death classification by end
point review committee
Guidant (unspecified type)
Continued on next page
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and 0.40, respectively. The results of CIDS and Wever et al.
independently showed a tendency to decreased arrhythmic
death with an ICD, with RR of 0.70 and 0.27, respectively.
When the studies were pooled (heterogeneity chi-square
3.6, p  0.3), there was a 50% reduction (95% CI 34% to
62%) in arrhythmic death with the defibrillator (p 
0.00001). The absolute reduction in arrhythmic death with
the ICD was 7% (95% CI 5% to 10%). There was no effect
on nonarrhythmic deaths with a RR of 0.95 (95% CI 0.71
to 1.27). Four studies reported all-cause mortality in sec-
ondary prevention. The AVID trial revealed a reduction in
deaths with the ICD. However, CASH, CIDS, and Wever
et al. did not independently show a mortality reduction.
When the trials were pooled using a fixed effects model (Fig.
4), the RR was 0.75 (95% CI 0.64 to 0.87), significantly
favoring the defibrillator (p  0.0002). The absolute reduc-
tion in all-cause mortality in secondary prevention was 7%
(95% CI 4% to 11%; number needed to treat: 15). The
survival benefit with the ICD was robust in sensitivity
analysis and not heavily influenced by any of the trials
individually (Table 2).
Overall analysis (all trials). When all trials reporting
arrhythmic deaths were pooled (Fig. 5), there was consis-
tency between the individual trial results and no statistical
evidence for heterogeneity (p  0.18). There was a 57%
reduction in risk of arrhythmic death with the ICD (p 
0.00001) and an 8% (95% CI 6% to 10%) absolute reduction
in arrhythmic death. The benefit of the defibrillator was
robust and was not sensitive to the exclusion of any
individual study in a sensitivity analysis, with no change in
the heterogeneity of the remaining studies or the signifi-
cance of the results. Overall, there was no excess of
nonarrhythmic deaths in the defibrillator group. The overall
RR of nonarrhythmic death from all trials combined was
0.95 (95% CI 0.79 to 1.15) with no heterogeneity between
studies (p  0.3). Pooling all trials showed a significant
reduction in the risk of all-cause death, with a 30%
reduction in death overall (random effects: p  0.001). The
absolute risk of death from any cause was reduced by 10%
(95% CI 4% to 16%). The findings for all-cause mortality
were again robust in sensitivity analysis.
Grouped clinical analyses. A series of sensitivity analyses
was conducted to explore the relative effects of the ICD in
differing clinical subgroups. For the primary prevention
trials studying patients with ischemic heart disease, the
pooled analysis favored the ICD (RR 0.64, 95% CI 0.41 to
0.98), with a significant reduction in all-cause mortality (p
 0.04). There was only one trial in nonischemic patients;
therefore, pooling was unnecessary. Of the four studies in
ischemic patients, only the CABG Patch study had
protocol-driven revascularization. The remaining three
studies (MUSTT, MADIT I and II) may have differed in
the potential for silent or residual ischemia. When the three
trials were combined, there was a reduction in RR of death
from any cause of 0.53 (95% CI 0.37 to 0.76; p  0.001).
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explored in a separate analysis. There were seven trials
supported by grants from ICD manufacturers, and pooling
these trials showed a 33% RR reduction (p  0.01). Of the
two trials without such industry support, the results re-
mained in favor of the defibrillator with a 25% reduction in
risk (p  0.001). Sensitivity analysis, excluding MADIT I
and II, still demonstrated significant benefit in favor of the
defibrillator for all-cause mortality (RR 0.73, 95% CI 0.57
Figure 2. Plot of left ventricular ejection fraction (LVEF) in the defibrillator intervention (horizontal axis) and control arms (vertical axis) of the included
randomized trials. Error bars are the reported standard deviations of LVEF in trial publications. Most of the points lie on the diagonal, suggesting that
the trials were balanced for LVEF in the study arms. MADIT I and CABG Patch point estimates overlap. MUSTT and Wever et al. point estimates
overlap. No standard deviation of LVEF was reported in MUSTT; only the point estimate is shown. AVID  Antiarrhythmics Versus Implantable
Defibrillators study; CABG Patch Coronary Artery Bypass Graft Patch Trial; CASH Cardiac Arrest Study Hamburg; CAT Cardiomyopathy Trial;
CIDS  Canadian Implantable Defibrillator Study; MADIT  Multicenter Automatic Defibrillator Implantation Trial; MUSTT  Multicenter
Unsustained Tachycardia Trial.
Figure 3. Death from all causes in the primary prevention defibrillator trials, pooled in a random effects model. For each randomized trial, the number of
deaths (n) and the number assigned (N) are shown. The rectangles represent the point estimates of the relative risk (RR) for individual studies, and the
95% confidence intervals (CI) are shown as bars. The overall pooled RR is 0.66 with a 95% CI of 0.46 to 0.96, which significantly favors treatment with
the defibrillator (p  0.03). The horizontal tips of the black diamond represent the 95% CI, and the midpoint of the diamond represents the point
estimate of the RR. df  degrees of freedom; other abbreviations as in Figure 2.
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to 0.94; p  0.01) and arrhythmic death (RR 0.44, 95% CI
0.35 to 0.56; p  0.001). Finally, when MUSTT was
excluded from the pooled analysis of primary prevention
trials, the impact of the ICD on arrhythmic death remained
significant with a RR of 0.45 (95% CI 0.26 to 0.78; p 
0.01). However, the reduction in risk of all-cause mortality
(RR 0.74; 95% CI 0.51 to 1.08) was no longer significant (p
 0.12).
Treatment-related complications. Perioperative death
complicating defibrillator implantation occurred in 1.2%
without concomitant thoracotomy and coronary artery by-
pass grafting; however, such deaths occurred in 5.5% of
patients in CABG Patch. Other commonly reported ad-
verse events (and weighted percentages) in the defibrillator
arm were infection (2.4%), hematoma or seroma (3.7%),
pericardial effusion or tamponade (0.6%), pneumothorax
(1.6%), lead dislodgement or fracture (2.3%), and device
malfunction (2.0%). Among the medical arms employing
antiarrhythmic agents, amiodarone pulmonary toxicity was
the most often reported adverse effect, occurring in 3.0% to
5.7% (weighted mean 4.8%) of patients by study termina-
tion.
DISCUSSION
Our meta-analysis demonstrated a significant survival ad-
vantage with the defibrillator for patients at risk of sudden
cardiac death. Pooling primary and secondary prevention
studies together, defibrillators were associated with a 57%
reduction in the risk of an arrhythmic death and a 30%
decrease in risk of all-cause mortality as compared with
medical therapy alone. When distinguishing primary from
secondary prevention studies, only the latter was associated
with a consistent reduction in total mortality. In contrast,
the impact of defibrillators on total mortality for primary
prevention was variable and heavily dependent on the
patient population examined. Notwithstanding the differ-
ential effect on total mortality, both primary and secondary
prevention trials were associated with a similar reduction in
the risk of arrhythmic death.
Implantable defibrillator and survival benefits. The ef-
fects of the ICD on outcomes in secondary prevention were
consistent with other investigators (28). Specifically, the
ICD was associated with a 50% RR reduction for arrhyth-
mic death and a 25% RR reduction for all-cause mortality
(both absolute risk reductions, 7%). The secondary preven-
tion trial results were robust and consistent from study to
study.
To our knowledge, ours is the first meta-analysis evalu-
ating the efficacy of defibrillators in primary prevention of
sudden cardiac death reporting random effects analyses in
the presence of between-study heterogeneity. Primary pre-
vention studies showed a variable effect on all-cause mor-
tality. A factor that may have contributed to the variability
Figure 4. All-cause mortality in pooled secondary prevention defibrillator trials. For each randomized trial, the number of deaths (n) and the number
assigned (N) are shown. The rectangles represent the point estimates of the relative risk (RR) for individual studies, and the 95% CI are shown as bars.
The overall pooled RR is 0.75 with a 95% CI of 0.64 to 0.87, which significantly favors treatment with the defibrillator (p  0.0002). The study results
were not heterogeneous (p 0.26), and together demonstrated significant reduction in death from any cause with the implantable cardioverter defibrillator.
The horizontal tips of the black diamond represent the 95% CI, and the midpoint of the diamond represents the point estimate of the RR. AVID 
Antiarrhythmics Versus Implantable Defibrillators study; CASH  Cardiac Arrest Study Hamburg; CIDS  Canadian Implantable Defibrillator Study;
df  degrees of freedom.
Table 2. Sensitivity Analysis of Secondary Prevention Trials*
Study
Removed RR 95% CI
Heterogeneity
(p value)
ICD
Benefit
(p value)
AVID (19) 0.81 0.67–0.98 0.34 0.03
CASH (21) 0.73 0.61–0.87 0.16 0.0004
CIDS (23) 0.69 0.57–0.84 0.28 0.0002
Wever et al. (27) 0.76 0.65–0.89 0.32 0.0005
*Removal of each study (shown in column 1) followed by re-analysis of the pooled
relative risk (RR) (column 2) and 95% confidence intervals (CI) (column 3) in the
remaining trials is shown. No significant heterogeneity was detected (as shown in
column 4). The results suggest that the significant overall benefit of defibrillators on
all-cause mortality in secondary prevention is preserved independent of the effects of
any individual study.
Abbreviations as in Table 1.
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in primary prevention studies may have been the underlying
cardiac substrate. Whereas the majority of primary preven-
tion studies included patients with ischemic heart disease,
CAT was the only trial that included exclusively patients
with nonischemic cardiomyopathy. The role of defibrillators
in the latter group may be clarified by trials that address this
subpopulation of patients with LV dysfunction. Yet, the
effect of prophylactic defibrillators on arrhythmic death in
the primary prevention population was surprisingly similar
and consistent with its risk reduction for arrhythmic death
in secondary prevention. Excluding the MUSTT trial, a
primary prevention study for which the ICD was arguably
based on selection rather than on randomization, the ICD
was associated with RR reductions of 50% and 45% for
arrhythmic death among the secondary and primary preven-
tion trials, respectively. Given that defibrillators do not
reduce the risk of nonarrhythmic death, the difference
between the ICD outcome effects for primary prevention
and secondary prevention relates to the baseline risk of
life-threatening arrhythmia. In short, the attenuated and
inconsistent effect of defibrillators on total mortality among
primary prevention patients directly reflects a more heter-
ogenous spectrum of risk for life-threatening arrhythmias in
the months and years that follow.
Risk stratification. If ultimately, the clinical effectiveness
(and economic impact) of the ICD reflects the baseline risk
of arrhythmic death in the population, it is incumbent upon
researchers and clinicians to stratify patients in accordance
with the risk of life-threatening arrhythmias. Our analysis
crudely stratified patients into those with and without
previous cardiac arrest or symptomatic ventricular tachycar-
dia. Arguably, this is the simplest form of risk stratification.
However, available evidence suggests that within each
subgroup, the baseline risk of a life-threatening arrhythmia
impacts upon the subsequent effectiveness of defibrillators
on total mortality. For example, within a secondary preven-
tion trial, a further high-risk subset included those with the
lowest ejection fractions (29,30).
In addition to underlying ejection fraction and previous
history of cardiac arrest, other important case-mix and
clinical factors may predict the risk of life-threatening
arrhythmic complications; these include age (30), functional
status (30), the etiology of cardiac disease (2,31), residual
ischemic burden (32–35), electrocardiographic indices (36–
38), and inducibility of arrhythmias at electrophysiologic
study (39–41). The incremental importance of other strat-
egies that delineate and/or modify the risk of life-
threatening complications (e.g., electrophysiologic study,
revascularization) requires further evaluation. We believe
that the magnitude of absolute survival benefit and the
cost-effectiveness of the ICD will depend on the efficiency
by which patients who are at high risk of arrhythmic death
can be identified in the population (42).
The methodology employed for stratification of risk of
arrhythmic death in future studies might include predictive
models or clinical decision aids from substudies of RCTs
(30,43). Simple clinical rules, such as those gleaned from
electrocardiographic analysis, may be clinically useful. Ulti-
mately, no single test may be highly predictive, and it may
require a combination of predictive tests to identify a
Figure 5. Impact of the randomized defibrillator trials on arrhythmic death. For each randomized trial, the number of arrhythmic deaths (n) and the number
assigned (N) are shown. All studies showed consistent benefit in reducing arrhythmic death with the implantable cardioverter defibrillator (ICD), and there
was no statistical heterogeneity between studies (p  0.18). Over all studies reporting arrhythmic deaths, the defibrillator reduced the risk of arrhythmic
death significantly (pooled relative risk 0.43; 95% CI 0.35 to 0.54). The ICD effect was a highly significant reduction in risk of arrhythmic death (p 
0.00001). The horizontal tips of the black diamond represent the 95% CI, and the midpoint of the diamond represents the point estimate of the RR.
CABG Patch  Coronary Artery Bypass Graft Patch Trial; MADIT  Multicenter Automatic Defibrillator Implantation Trial; MUSTT  Multicenter
Unsustained Tachycardia Trial. Other abbreviations as in Figure 4.
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high-risk subset (44). In addition to the need for further
study of the prognostic value of diagnostic tests, equally
important may be the consideration of patient-related fac-
tors. This includes consideration of the cardiac substrate and
comorbidities. Factors that predict high utility of the ICD
in patients with ischemic heart disease may not apply to
those with nonischemic cardiomyopathy. In addition, non-
cardiac comorbidities may lead to mechanisms of death for
which the ICD would not change the disease history and
the ultimate prognosis of the patient. This concept of
competing risks may diminish the effectiveness of the
defibrillator on all-cause mortality (45). Studies that include
patients who are similar to those that clinicians encounter in
real-world practice may offer insight.
Study limitations. There are several noteworthy limita-
tions to our study. First, our study was limited by the
relative paucity of primary prevention defibrillator trials. For
example, we had only one trial in nonischemic cardiomy-
opathy, which may complement our primary prevention
analysis of patients with coronary artery disease. Additional
randomized trials of ICD strategies in patients with coro-
nary artery disease will help to increase further the precision
of the estimated benefits of the defibrillator and may lead to
greater robustness of our results. A number of pending
publications of randomized trials, including Amiodarone
Versus Implantable Defibrillator in Patients with Nonisch-
emic Cardiomyopathy and Asymptomatic Nonsustained
Ventricular Tachycardia (AMIOVIRT), Beta-blocker
Strategy plus Implantable Cardioverter Defibrillator Trial
(BEST-ICD), Defibrillators in Nonischemic Cardiomyop-
athy Treatment Evaluation (DEFINITE), Defibrillator in
Acute Myocardial Infarction Trial (DINAMIT), and Sud-
den Cardiac Death in Heart Failure Trial (SCD-HEFT),
may further improve the reliability of the primary preven-
tion estimates of ICD effect. Second, there may be other
reasons for statistical and clinical heterogeneity that could
not be realized from this analysis, such as the effects of
variable follow-up times. An analysis of pooled survival time
data may yield further insights. Third, studies with arrhyth-
mic death end points are limited by the accuracy of death
classification methods, and the further subclassification of
arrhythmic deaths as bradyarrhythmic or tachyarrhythmic
deaths may be limited without studies employing combined
ventricular pacemaker and defibrillator. Fourth, no cost-
effectiveness analysis was undertaken. Nonetheless, the ro-
bust estimates of event rates as determined by our study may
set the stage for future ICD cost-benefit analysis.
Conclusions. The defibrillator is highly effective in reduc-
ing the risk of arrhythmic death when used in either a
primary or secondary prevention context. Pooled analysis of
all-cause mortality showed a reduction in risk of death with
defibrillator implantation. While the secondary prevention
results were robust, primary prevention findings were sen-
sitive to the contributions of individual trials. Given the
fiscal implications of the primary prevention trials, we
believe that the impact of device implantation strategies on
health policy, cost-effectiveness, and access to this form of
therapy should be further evaluated. Our results suggest that
net survival benefits and cost-effectiveness of the ICD when
applied to the population will depend upon efficient use of
devices for those at highest risk of life-threatening arrhyth-
mias.
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